LIFECORE BIOMEDICAL, INC. Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
LIFECORE BIOMEDICAL, INC. (LFCR) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of -$344.00 thousand for the 12-month period ending 2021-05-30, per its 10-K filed 2024-03-20.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2024-03-20
- LIFECORE BIOMEDICAL, INC. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2021 was -$344.00K.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month |
|---|---|
| 2021-05-30 | -$344.00K 10-K · filed 2024-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |